Streetbeat News

Revenues

WSR

Analyst ratings for Whitestone REIT (NYSE:WSR) have varied over the past three months, with a recent consensus moving towards a somewhat bullish outlook. The latest ratings include one 'Market Outperform' and one 'Buy', both with a price target of $15.00, marking a 15.38% increase from the previous target of $13.00. Whitestone REIT's financial performance shows a revenue growth of 5.84% for the last quarter of 2023 but falls below industry averages in market capitalization, net margin, ROE, and ROA, indicating potential challenges in profitability and asset management.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 5:00 pm

BTCUSD

Deutsche Bank's survey indicates a rise in positive sentiment towards cryptocurrencies among retail investors in Q1 2024, despite concerns over a potential major cryptocurrency collapse. The approval of spot Bitcoin ETFs in January 2024 has contributed to a crypto market rally. However, opinions on Bitcoin's future remain divided, with a significant portion of U.S. consumers viewing cryptocurrencies as commodities and a potential replacement for cash.

Portfolio Pulse from Khyathi Dalal

April 10, 2024 | 4:25 pm

EU

UEC

UUUU

North American uranium miners are experiencing a resurgence due to a push from U.S. politicians to reduce dependency on Russian uranium and the nuclear industry's revival for decarbonizing electricity. Uranium prices remain high despite a recent pullback, nearly tripling over the past three years. Companies like Energy Fuels Inc., Denison Mines Corp., Uranium Energy Corp., Ur-Energy Inc., IsoEnergy Ltd., and Global Atomic Corp. are increasing production capacity. Global Atomic is advancing its Dasa project in Niger, expected to be a profitable venture for over 40 years. Energy Fuels is diversifying into vanadium and rare earths, while Uranium Energy plans to restart Wyoming production by August. enCore Energy Corp. has announced its first shipment from the Rosita plant in South Texas and is working on restarting its Alta Mesa plant.

Portfolio Pulse from Matt Whittaker

April 10, 2024 | 4:24 pm

APRE

Aprea Therapeutics announced presentations on APR-1051 and ATRN-119 at AACR Annual Meeting 2024, highlighting pre-clinical and clinical updates. APR-1051, a WEE1 kinase inhibitor, shows potential for treating Cyclin E-overexpressing cancers with minimal off-target effects and low cardiotoxicity. ATRN-119, an ATR inhibitor, demonstrated safety and preliminary clinical benefit in an ongoing study. The company plans to initiate a Phase 1 trial for APR-1051 in June 2024.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 4:02 pm

RYTM

Analysts have mixed views on Rhythm Pharmaceuticals (NASDAQ:RYTM), with recent ratings varying from bullish to bearish. The average 12-month price target is $50.8, reflecting a 20.95% increase from the previous target of $42. Rhythm Pharmaceuticals, a biopharmaceutical company, has shown a revenue growth of 175.7% as of December 31, 2023, but trails behind industry peers in the Health Care sector. Its net margin and ROE are below industry standards, indicating potential challenges in profitability and equity capital utilization.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 4:00 pm

WEN

In the past three months, Wendy's (NASDAQ:WEN) received 10 analyst ratings, showing a mix of perspectives. The recent ratings indicate a shift towards a more cautious stance, with a notable decline in the average 12-month price target to $20.1, down 8.64% from the previous target. Analysts from firms like TD Cowen, Bernstein, and JP Morgan have adjusted their ratings and price targets, reflecting changes in market conditions and Wendy's performance. Wendy's, a leading burger QSR in the US, reported a revenue growth of 0.77% as of December 31, 2023, and outperforms in net margin and ROE but has a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 4:00 pm

OVV

Analyst ratings for Ovintiv (NYSE:OVV) show a mix of bullish and bearish perspectives with 8 analysts providing ratings in the past three months. The average 12-month price target is $56.38, reflecting a 10.85% increase from the previous target of $50.86. Analyst actions include maintaining, raising, and lowering ratings and price targets, indicating varied perceptions of Ovintiv's market position. The company faces challenges in revenue growth, profitability, and debt management but excels in asset management.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 4:00 pm

AXSM

Analyst ratings for Axsome Therapeutics (NASDAQ:AXSM) show a diverse range of perspectives, with a notable shift towards more bullish sentiments in the last three months. The average 12-month price target for AXSM has increased to $130.3, reflecting a positive outlook on the company's future. Axsome Therapeutics, a clinical-stage biopharmaceutical company, has shown significant revenue growth of 193.5% as of December 31, 2023, outperforming its peers in the Health Care sector. However, challenges such as a net margin of -137.92% and a high debt-to-equity ratio of 0.98 indicate potential financial hurdles.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 4:00 pm

AAPL

GLD

SPY

USO

New data indicates higher-than-expected inflation, suggesting a potential pullback in the stock market, though the bull market remains intact. The Arora Report plans to buy on the pullback, advising investors to increase cash holdings and adjust hedges. Early trade shows negative money flows in major tech stocks and ETFs, with the momo crowd buying stocks and gold, while smart money sells. Oil sees a build in inventories, and Bitcoin drops on the inflation news, challenging its status as an inflation hedge.

Portfolio Pulse from The Arora Report

April 10, 2024 | 3:36 pm

CHTR

CMCSA

T

VZ

AT&T Inc (T), Charter Communications, Inc (CHTR), Comcast Corp (CMCSA), and Verizon Communications Inc (VZ) face challenges as a federal program providing discounted internet to 23 million households faces cuts in May. The FCC will reduce the maximum subsidy to $14/month, impacting low-income families' access to internet services. The future of the Affordable Connectivity Program (ACP) depends on providers' willingness to extend discounts post-subsidy reduction. The White House seeks emergency funding for ACP, while some lawmakers question its value.

Portfolio Pulse from Anusuya Lahiri

April 10, 2024 | 3:31 pm